Evidence map›Paper›PMID 27880976›Full record

ArticleHepatology (Baltimore, Md.)2017

A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.

Xiaohua Chen, Odgerel Oidovsambuu, Ping Liu, Rosslyn Grosely, Menashe Elazar, Virginia D Winn, Benjamin Fram, Zhang Boa, Hongjie Dai, Bekhbold Dashtseren and 6 more

Open access · bronzeAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment-naïve HBV/HDV Co-Infected Patients.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Hepatitis Delta Virus and Hepatocellular Carcinoma.Pathogens (Basel, Switzerland) · 2024
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Xiaohua ChenDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA.
Odgerel OidovsambuuLiver Center, Ulaanbaatar, Mongolia.
Ping LiuDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA.
Rosslyn GroselyDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA.
Menashe ElazarDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA.
Virginia D WinnDepartment of Obstetrics and Gynecology, Stanford University, Palo Alto, CA.
Benjamin FramDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA.
Zhang BoaDepartment of Chemistry, Stanford University, Palo Alto, CA.
Hongjie DaiDepartment of Chemistry, Stanford University, Palo Alto, CA.
Bekhbold DashtserenLiver Center, Ulaanbaatar, Mongolia.
Dahgwahdorj YagaanbuyantLiver Center, Ulaanbaatar, Mongolia.
Zulkhuu GendenLiver Center, Ulaanbaatar, Mongolia.
Naranbaatar DashdorjOnom Foundation, Ulaanbaatar, Mongolia.
Andreas BungertOnom Foundation, Ulaanbaatar, Mongolia.
Naranjargal DashdorjLiver Center, Ulaanbaatar, Mongolia.
Jeffrey S GlennDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA.
Stanford University · USMongolian National University · MN

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Translational Incubator CoreU19AI109662 · NIAID · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2014 to 2019
$28.6M
Functional significance of Siglec-6, a novel leptin receptor, in human placentalR01HD060723 · NICHD · UNIVERSITY OF COLORADO DENVER · PI WINN, VIRGINIA D · 2010 to 2014
$1.5M
NCATS NIH HHS UL1 TR001082NCRR NIH HHS UL1 RR025780NIAID NIH HHS U19 AI109662NICHD NIH HHS R01 HD060723
6 · The paper itself

Abstract

Hepatitis delta virus (HDV) causes the most severe form of human viral hepatitis. HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with HBV surface antigen envelope proteins. The net effect of HDV is to make the underlying HBV disease worse, including higher rates of hepatocellular carcinoma. Accurate assessments of current HDV prevalence have been hampered by the lack of readily available and reliable quantitative assays, combined with the absence of a Food and Drug Administration-approved therapy. We sought to develop a convenient assay for accurately screening populations and to use this assay to determine HDV prevalence in a population with abnormally high rates of hepatocellular carcinoma. We developed a high-throughput quantitative microarray antibody capture assay for anti-HDV immunoglobulin G wherein recombinant HDV delta antigen is printed by microarray on slides coated with a noncontinuous, nanostructured plasmonic gold film, enabling quantitative fluorescent detection of anti-HDV antibody in small aliquots of patient serum. This assay was then used to screen all HBV-infected patients identified in a large randomly selected cohort designed to represent the Mongolian population. We identified two quantitative thresholds of captured antibody that were 100% predictive of the sample either being positive on standard western blot or harboring HDV RNA detectable by real-time quantitative PCR. Subsequent screening of the HBV

conclusionThe quantitative microarray antibody capture assay's unique performance characteristics make it ideal for population screening; its application to the Mongolian HBV surface antigen-positive population reveals an apparent ∼60% prevalence of HDV coinfection among these HBV-infected Mongolian subjects, which may help explain the extraordinarily high rate of hepatocellular carcinoma in Mongolia. (Hepatology 2017;66:1739-1749).

Indexed as

Antibodies, ViralBlotting, WesternCase-Control StudiesCoinfectionEnzyme-Linked Immunosorbent AssayFemaleHepatitis BHepatitis DHepatitis Delta VirusHumansMicroarray AnalysisMongoliaPregnancyPrevalenceSensitivity and SpecificityAntibodies, Viral

Identifiers

PMID27880976
PMCPMC5441964
OpenAlexW2786175833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.